Company Overview - Vicarious Surgical is developing a next-generation surgical robot designed for general surgery, leveraging decoupled actuators for enhanced ease of use, clinical outcomes, and economics [9] - The company anticipates first human use of its V1.0 System in late 2025 and an FDA De Novo submission in late 2026 [12] - Vicarious Surgical has attracted top-tier partners, including HCA, multiple hospital systems, and leading investors [10] Market Opportunity - The initial market opportunity is estimated at $150 billion [15], addressing 45 million abdominal procedures worldwide per year [16] - Currently, only ~4% of these procedures are performed robotically [16], indicating a 96% whitespace [13] - Existing robots are primarily designed for prostate surgery, one of the lowest volume abdominal procedures [19] Technology and Benefits - The Vicarious Surgical System utilizes a single 1.8cm incision [43], aiming to reduce incisional complication rates compared to open and multi-port techniques [43] - The system offers 9 degrees of freedom per arm through a single incision [47], enabling complete anatomical access and surgeon-equivalent robotic motion [47] compared to the 4 degrees of freedom in roboticized laparoscopy [46] - Hospital contribution with Vicarious Surgical is projected to be $6,237 compared to -$10,139 with multi-port systems [50] Future Development - The company is positioned for AI-automated surgery, capturing over 1 GB of data per second to train its models [61] - Vicarious Surgical is developing AI-assisted surgery features, starting with intra-operative alerts and guidance [62]